Hydrogen sulfide mitigates cardiac remodeling during myocardial infarction via improvement of angiogenesis

International Journal of Biological Sciences

Volumn 8, Issue 4, 2012, Pages 430-441

  Qipshidze, Natia ^a   Metreveli, Naira ^a   Mishra, Paras K ^a   Lominadze, David ^a   Tyagi, Suresh C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Angiostatin; Endostatin; flk 1; flt 1; Hydrogen sulfide; Parstatin myocardial infarction; VEGF

Indexed keywords

ANGIOSTATIN; ENDOSTATIN; HYDROGEN SULFIDE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL; ARTICLE; CONFOCAL MICROSCOPY; DRUG EFFECT; ECHOCARDIOGRAPHY; GENETICS; HEART INFARCTION; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANGIOSTATINS; ANIMALS; BLOTTING, WESTERN; ECHOCARDIOGRAPHY; ENDOSTATINS; HYDROGEN SULFIDE; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICROSCOPY, CONFOCAL; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MUS;

EID: 84857944770     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.3632     Document Type: Article

References (51)

1. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early Expression of Angiogenesis Factors in Acute Myocardial Ischemia and Infarction. New England Journal of Medicine 2000,342:626-633.
2. Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP, Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. American Journal of Physiology - Heart and Circulatory Physiology 1996,270:H1803-H1811.
3. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005,69: 4-10.
4. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005:209-231.
5. Goodsell DS. The Molecular Perspective: VEGF and Angiogenesis. Oncologist 2002,7:569-570.
6. LeCouter J LR, Ferrara N. The role of EG-VEGF in the regulation of angiogenesis in endocrine glands. Cold Spring Harbor Symposia on Quantitative Biology 2002,67:217-221.
7. McColl BK, Stacker SA, Achen MG. Molecular regulation of the VEGF family - inducers of angiogenesis and lymphangiogenesis. APMIS 2004,112:463-480.
8. McMahon G. VEGF Receptor Signaling in Tumor Angiogenesis. Oncologist 2000,5:3-10.
9. Banai S SD, Pinson A, Chandra M, Lazarovici G, Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovascular research 1994,28:1176-1179.
10. Sharma HS WM, Schmidt M, Schott RJ, Kandolf R, Schaper W. Expression of angiogenic growth factors in the collateralized swine myocardium. EXS 1992,61:255-260.
11. Hashimoto E, Ogita T, Nakaoka T, Matsuoka R, Takao A, Kira Y. Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. American Journal of Physiology - Heart and Circulatory Physiology 1994,267:H1948-H1954.
12. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochemical and Biophysical Research Communications 1992,187:1579-1586.
13. Patterson C, Perrella MA, Endege WO, Yoshizumi M, Lee ME, Haber E. Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. The Journal of Clinical Investigation 1996,98:490-496.
14. Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. American Journal of Physiology - Lung Cellular and Molecular Physiology 2006,290:L209-L221.
15. Couffinhal T SM, Kearney M, Sullivan A, Witzenbichler B, Magner M, Annex B, Peters K, Isner JM. Impaired Collateral Vessel Development Associated With Reduced Expression of Vascular Endothelial Growth Factor in ApoE-/- Mice. Circulation 1999,99:3188-3198.
16. Rivard A, Berthou-Soulie L, Principe N, Kearney M, Curry C, Branellec D, et al. Age-dependent Defect in Vascular Endothelial Growth Factor Expression Is Associated with Reduced Hypoxia-inducible Factor 1 Activity. Journal of Biological Chemistry 2000,275:29643-29647.
17. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B, et al. Rescue of Diabetes-Related Impairment of Angiogenesis by Intramuscular Gene Therapy with Adeno-VEGF. The American Journal of Pathology 1999,154:355-363.
18. Qipshidze N, Tyagi N, Sen U, Givvimani S, Metreveli N, Lominadze D, et al. Folic acid mitigated cardiac dysfunction by normalizing the levels of tissue inhibitor of metalloproteinase and homocysteine-metabolizing enzymes postmyocardial infarction in mice. American Journal of Physiology - Heart and Circulatory Physiology 2010,299:H1484-H1493.
19. Duan J MT, Ikeda H, Katoh A, Shintani S, Sasaki K, Kawata H, Yamamoto N, Imaizumi T. Hypercholesterolemia Inhibits Angiogenesis in Response to Hindlimb Ischemia: Nitric Oxide-Dependent Mechanism. Circulation 2000,102:3-370-376.
20. Nagai Y, Tasaki H, Takatsu H, Nihei S-i, Yamashita K, Toyokawa T, et al. Homocysteine Inhibits Angiogenesis in Vitro and in Vivo. Biochemical and Biophysical Research Communications 2001,281:726-731.
21. Zhao W, Wang R. H2S-induced vasorelaxation and underlying cellular and molecular mechanisms. American Journal of Physiology - Heart and Circulatory Physiology 2002,283:H474-H480.
22. Geng B, Yang J, Qi Y, Zhao J, Pang Y, Du J, et al. H2S generated by heart in rat and its effects on cardiac function. Biochemical and Biophysical Research Communications 2004,313:362-368.
23. Zhang Z HH, Liu P, Tang C, Wang J. Hydrogen sulfide contributes to cardioprotection during ischemia-reperfusion injury by opening K ATP channels. Canadian Journal of Physiology and Pharmacology 2007,85:1248-1253.
24. Sodha NR, Clements RT, Feng J, Liu Y, Bianchi C, Horvath EM, et al. The effects of therapeutic sulfide on myocardial apoptosis in response to ischemia-reperfusion injury. European Journal of Cardio-Thoracic Surgery 2008,33:906-913.
25. Givvimani S, Munjal C, Gargoum R, Sen U, Tyagi N, Vacek JC, et al. Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure. Journal of Applied Physiology 2011,110:1093-1100.
26. Duncan MB, Kalluri R. Parstatin, a Novel Protease-Activated Receptor 1-Derived Inhibitor of Angiogenesis. Molecular Interventions 2009,9:168-170.
27. Frank KF, Müller-Ehmsen J. Angiostatin: drying out the roots in cardiac muscle. Heart 2009,95:269-270.
28. Jing Q, Xinyu Q, Rougcheng L. Recombinant Human Endostatin-associated Acute Left Heart Failure. Clinical Oncology 2008,20:268-268.
29. Yamahara K, Min KD, Tomoike H, Kangawa K, Kitamura S, Nagaya N. Pathological role of angiostatin in heart failure: an endogenous inhibitor of mesenchymal stem-cell activation. Heart 2009,95:283-289.
30. Givvimani S, Tyagi N, Sen U, Mishra PK, Qipshidze N, Munjal C, et al. MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure*. Archives Of Physiology And Biochemistry 2010,116:63-72.
31. Sen U, Tyagi N, Patibandla PK, Dean WL, Tyagi SC, Roberts AM, et al. Fibrinogen-induced endothelin-1 production from endothelial cells. American Journal of Physiology - Cell Physiology 2009,296:C840-C847.
32. Wilkinson IB, MacCallum H, Cockcroft JR, Webb DJ. Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo. British Journal of Clinical Pharmacology 2002,53:189-192.
33. Lominadze D, Schuschke DA, Joshua IG, Dean WL. Increased ability of erythrocyrtes to aggregate in spontaneously hypertensive rats. Clinical and Experimental Hypertension 2002,24:397-406.
34. Tyagi N, Ovechkin AV, Lominadze D, Moshal KS, Tyagi SC. Mitochondrial mechanism of microvascular endothelial cells apoptosis in hyperhomocysteinemia. Journal of Cellular Biochemistry 2006,98:1150-1162.
35. Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, et al. Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proceedings of the National Academy of Sciences 2007,104:15560-15565.
36. Johansen D, Ytrehus K, Baxter G. Exogenous hydrogen sulfide (H2S) protects against regional myocardial ische-mia-reperfusion injury--Evidence for a role of K ATP channels. Basic Research in Cardiology 2006,101:53-60.
37. Li L, Moore PK. Putative biological roles of hydrogen sulfide in health and disease: a breath of not so fresh air? Trends in Pharmacological Sciences 2008,29:84-90.
38. Sivarajah A, McDonald MC, Thiemermann C. The Production of Hydrogen Sulfide Limits Myocardial Ischemia and Reperfusion Injury and Contributes To the Cardioprotective Effects of Preconditioning With Endotoxin, But Not Ischemia in the Rat. Shock 2006,26:154-161.
39. Szabo C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 2007,6:917-935.
40. Sen U MC, Qipshidze N, Abe O, Gargoum R, Tyagi SC. Hydrogen sulfide regulates homocysteine-mediated glomerulosclerosis. American Journal of Nephrology 2010,31:442-455.
41. Laham RJ LJ, Tofukuji M, Post M, Simons M, Sellke FW. Spatial heterogeneity in VEGF-induced vasodilation: VEGF dilates microvessels but not epicardial and systemic arteries and veins. Annals of vascular surgery 2003,17:245-252.
42. Lopez JJ, Laham R, Stamler A, Pearlman JD, Bunting S, Kaplan A, et al. VEGF administration in chronic myocardial ischemia in pigs. Cardiovascular research 1998,40:272-281.
43. Sato K, Wu T, Laham RJ, Johnson RB, Douglas P, Li J, et al. Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. Journal of the American College of Cardiology 2001,37:616-623.
44. Wu G, Luo J, Rana JS, Laham R, Sellke FW, Li J. Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovascular research 2006,69:512-519.
45. Risau W. Mechanisms of angiogenesis. Nature 1997,386:671-674
46. House SL, Bolte C, Zhou M, Doetschman T, Klevitsky R, Newman G, et al. Cardiac-Specific Overexpression of Fibroblast Growth Factor-2 Protects Against Myocardial Dysfunction and Infarction in a Murine Model of Low-Flow Ischemia. Circulation 2003,108:3140-3148.
47. Sorensen Dag R. R, Tracy-Ann Porwol Torsten., Olsen, Bjorn R., Timpl, Rupert., Sasaki, Takako., Iversen, Per O., Benestad, Haakon B., Lee Sim., Bjerkvig, Rolf. Endostatin reduces vascularization, blood flow, and growth in a rat gliosarcoma. Neuro-Oncology 2002,4:1-8.
48. Moser TL, Stack MS, Asplin I, Enghild JJ, Højrup P, Everitt L, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 1999,96:2811-2816.
49. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 1999,18:4414-4423.
50. Hajitou A, Grignet-Debrus C, Devy L, Berndt S, Blacher S, Deroanne CF, et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. The FASEB Journal 2002,16:1802-1804.
51. Claesson-Welsh L, Welsh M, Ito N, Anand-Apte B, Soker S, Zetter B, et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proceedings of the National Academy of Sciences of the United States of America 1998,95:5579-5583.